Ribomic News

Ribomic: A transcript of our financial results briefing for the 2nd quarter (interim period) of the fiscal year ending 2025/3 was published on Logme Finance

01:30 ET

Ribomic: Notice regarding the monthly exercise status of the 17th Stock Acquisition Rights (with exercise price amendment clause)

Dec 2 01:30 ET

Ribomic: Notice of video distribution of the financial results briefing for the 2nd quarter (interim period) of the fiscal year ending 2025/3

Nov 27 01:30 ET

Ribomic: Notice of patent assessment in Taiwan for application patents relating to umedaptanib pegol (anti-FGF2 aptamer)

Nov 19 01:30 ET

Ribomic: Notice regarding presentation of research results for quantum and AI next-generation drug discovery

Nov 15 01:30 ET

Ribomic: Notice of MOU signing with King Abdullah International Medical Research Center

Nov 13 01:30 ET

Ribomic: Summary of Non-Consolidated Financial Results for the Six Months Ended September 30 2024(Based on Japanese GAAP)

Nov 12 01:30 ET

Ribomic: Notice regarding the recording of non-operating income (grant revenue) and non-operating losses (exchange losses)

Nov 12 01:30 ET

Ribomic: Notice of confirmation of remarkable effects (increase in growth rate) in the low dose group in early phase II clinical trials for achondroplasia (umedaptanib pegol)

Nov 5 01:30 ET

Ribomic: Notice regarding the monthly exercise status of the 17th Stock Acquisition Rights (with exercise price amendment clause)

Nov 1 02:00 ET

Ribomic: Announcement of invited talks at The Riyadh Global Medical Biotechnology Summit

Oct 24 02:00 ET

Ribomic: Presentation materials at the International Skeletal Dysplasia Society international conference

Sep 25 02:00 ET

Ribomic: Notice of NEDO's “Cyber-Physical Development Project for Quantum-Classical Hybrid Technology” Stage Gate Examination Passed

Sep 24 02:00 ET

Ribomic: Presentation materials at The Retina Society international conference

Sep 18 02:00 ET

Ribomic: Notice of European Patent Registration for Formulation Patents Related to umedaptanib pegol (anti-FGF2 aptamer)

Sep 12 23:00 ET

Ribomic: Notice regarding the monthly exercise status of the 17th Stock Acquisition Rights (with exercise price amendment clause)

Sep 2 02:00 ET

Ribomic: Announcement of individual stocks: Notification of presentation at the International Skeletal Dysplasia Society conference

Aug 14 02:00 ET

Ribomic: Announcements of individual stocks regarding the recognition of non-operating income (foreign exchange gains)

Aug 9 02:00 ET

Ribomic: Overview of non-consolidated financial statements for the three-month period ending on June 30, 2024 (based on Japanese accounting standards).

Aug 9 02:00 ET

Ribomic: [Delayed] RIBOMIC has announced the completion of patient registration for the initial Phase II trial of Umedaptanib Pegol for achondroplasia.

Aug 2 02:00 ET